Gonasi Set

Gonasi Set is a prescription injectable solution that contains the active ingredient human chorionic gonadotropin (hCG). It is supplied in a dosage form intended for intramuscular or subcutaneous administration and is marketed in the European Union. As a gonadotropin, Gonasi Set mimics luteinizing hormone activity to support ovulation and the luteal phase in assisted reproductive protocols. It is prescribed for infertility treatments and should be handled according to the instructions.

Gonasi Set is indicated for several fertility‑related purposes in assisted reproductive technology.

- Induction of ovulation in women with anovulatory or oligo‑ovulatory disorders. - Luteal phase support following ovulation induction or assisted conception cycles. - Treatment of infertility associated with inadequate endogenous hCG production. - Use in combination with gonadotropin‑releasing hormone (GnRH) protocols to trigger final oocyte maturation. - Support of spermatogenesis in selected male infertility cases (off‑label in some regions).

Side effects reported with Gonasi Set vary in frequency and severity; they are generally related to the injection site or hormonal activity.

Common: - Injection‑site pain, redness, or swelling. - Mild headache or fatigue. - Nausea or mild abdominal discomfort. - Temporary ovarian enlargement or cyst formation. - Breast tenderness or mild edema.

Serious: - Ovarian hyperstimulation syndrome (OHSS) with rapid weight gain, ascites, or respiratory distress. - Allergic reactions such as rash, itching, or anaphylaxis. - Thromboembolic events including deep‑vein thrombosis. - Ectopic pregnancy in the setting of assisted conception.

Before prescribing Gonasi Set, clinicians should evaluate patient history and monitor for conditions that could be worsened by hCG therapy.

- Confirm absence of active ovarian cysts or severe endometriosis. - Assess risk factors for ovarian hyperstimulation syndrome, especially in polycystic ovary syndrome. - Review personal or family history of thromboembolic disease. - Ensure appropriate timing within the menstrual cycle to avoid premature luteinization. - Monitor serum estradiol and hCG levels during treatment. - Use caution in patients with uncontrolled thyroid disease due to hCG’s thyrotropic effect.

Gonasi Set may interact with other medications or hormonal agents, influencing efficacy or safety.

Avoid: - Concurrent use of other gonadotropins or hCG products, which can cause excessive hormonal stimulation. - High‑dose estrogen therapy that may mask ovarian response.

Use with caution: - Anticoagulant or antiplatelet drugs, due to increased risk of thrombosis in OHSS. - Thyroid hormone replacement, as hCG can affect thyroid function tests. - Assisted reproductive protocols involving GnRH agonists or antagonists, requiring dose adjustments.